This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

About

Burden of Disease

Burden of Disease

Description of the DiseaseGlobal EpidemiologyIndian EpidemiologyPneumococcal Disease and InfluenzaChallenges

Risk Factors
 

Risk Factors

Secondary Infections
​​​​​​​

Secondary Infections

Mechanism of Action
​​​​​​​

Mechanism of Action

Prevention of Pneumococcal Disease
 

Polysaccharide VaccineConjugate VaccineDifference

Need for Pneumococcal Vaccination

In ElderlyIn India

Cost-effectiveness of PCV13
 

NeedIndian StudiesGlobal Studies

Legacy of Prevenar
 

ManufacturingCRM197Activation and ConjugationPneumococcal Disease and InfluenzaDistributionVideos

Safety
 

Safety

Conclusion
 

Conclusion
Dosing

Dosing
 

Adults ≥18 Years of AgeAdults ≥50 Years of AgeCOVID VaccinationFlu Vaccination
Efficacy

Prevenar 13® Clinical Experience
 

IntroductionClinical Trials

Efficacy of Prevenar 13®
 

IntroductionStudyObjectiveMethodologyCriteriaResultsConclusion

Effectiveness of Prevenar 13® 
 

IntroductionObjectiveMethodologyAnalysisResultsLimitationsLearningsConclusion

Indian Clinical Trials
 

IntroductionStudy DesignResultsLimitationsConclusion
Recommendations for Use

Recommendations for Use
 

ACIP 2019NCCN 2020RSSDI 2020IMA GuidelinesIAOH Guidelines for Working AdultsClinical Practice Guidelines 2019 (ICS/NCCP)The Geriatric Society of India, 2015Indian Society of Nephrology
FAQs

PCV13 in Pulmonology
 

RoleComplicationsClinical DataRecommendations

PCV13 in Nephrology
 

RoleClinical DataRecommendations

PCV13 in Oncology
 

RoleClinical DataRecommendations

PCV13 in Rheumatology
 

RoleComplicationsDataRecommendationsConsensus

PCV13 in Diabetes
 

RoleComplicationsDataRecommendations

PCV13 in HIV Infection
 

RoleBurdenPulmonary InfectionDataEfficacyRecommendations

PCV13 in Cardiology
 

RoleBurdenComplicationsDataRecommendations
Resources

Resources

Summary of Prescribing InformationDownloadable ResourcesEvents and WebinarsLatest Articles

Example

OnOne month after vaccination, OPA GMTs in the PCV13 group were statistically higher than those in the PPSV23 group for 8 of the 12 serotypes (1, 4, 6B, 7F, 9V, 18C, 19A, 23F) common to both vaccines and for serotype 6A, a serotype unique to PCV13.
​​​​​​​
Patients with chronic stable medical disorders such as diabetes mellitus, cardiovascular diseases and chronic pulmonary diseases had similar immune responses as the normal population. However, the sample size for such patients was small for the possibility of a statistical analysis.3-5

A study evaluated immune responses in older adults, who had been vaccinated with PPSV23 at least 5 years before enrolment in the study.1,2 These patients were vaccinated with either PCV13 or PPSV23. The comparison of immune responses observed is shown in the figure below.


OnOne month after vaccination, OPA GMTs in the PCV13 group were statistically higher than those in the PPSV23 group for 8 of the 12 serotypes (1, 4, 6B, 7F, 9V, 18C, 19A, 23F) common to both vaccines and for serotype 6A, a serotype unique to PCV13.
​​​​​​​
Patients with chronic stable medical disorders such as diabetes mellitus, cardiovascular diseases and chronic pulmonary diseases had similar immune responses as the normal population. However, the sample size for such patients was small for the possibility of a statistical analysis.3-5

A study evaluated immune responses in older adults, who had been vaccinated with PPSV23 at least 5 years before enrolment in the study.1,2 These patients were vaccinated with either PCV13 or PPSV23. The comparison of immune responses observed is shown in the figure below.


Example

Example

Clinical Trials

A study evaluated the immune responses in older adults, who were not exposed to PPSV23 previously (vaccine-naïve adults).1,2 The results for the OPA GMT ratios for individual serotypes (1 month after dose) are as shown in the figure below.1,2

   

   

One month after vaccination, OPA GMTs in the PCV13 group were statistically higher than those in the PPSV23 group for 8 of the 12 serotypes (1, 4, 6B, 7F, 9V, 18C, 19A, 23F) common to both vaccines and for serotype 6A, a serotype unique to PCV13.1   

  

Patients with chronic stable medical disorders such as diabetes mellitus, cardiovascular diseases and chronic pulmonary diseases had similar immune responses as the normal population. However, the sample size for such patients was small for the possibility of a statistical analysis.3-5

   

A study evaluated immune responses in older adults, who had been vaccinated with PPSV23 at least 5 years before enrolment in the study.1,2 These patients were vaccinated with either PCV13 or PPSV23. The comparison of immune responses observed is shown in the figure below.

   

   

The immune responses observed on revaccination with Prevenar 13® (PCV13) in those who were previously vaccinated with PPSV23 were superior to those revaccinated with PPSV23, for 11 of the 13 serotypes, and non-inferior for all the 13 serotypes.1,2   

   

This indicates that vaccination with Prevenar 13® (PCV13) in adults previously vaccinated with PPSV23 elicits superior responses as compared with revaccination with PPSV23. The US ACIP Adult Immunization Schedule also recommends the sequential use of conjugate and polysaccharide vaccines in certain risk conditions.6

   

   

ACIP, Advisory Committee on Immunization Practices; GMT, geometric mean titre; OPA, opsonophagocytosis assay; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; US, United States.    

   

References:

Prevenar 13. Local product document. Pfizer. Version LPDPRV052021.Sanford M. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): in older adults. Drugs. 2012;72(9):1243-1255.Dey AB, Nagarkar KM, Kumar V. Clinical presentation and predictors of outcome in adult patients with community-acquired pneumonia. Natl Med J India. 1997;10(4):169-172.Jackson LA, Neuzil KM. Pneumococcal polysaccharide vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Saunders, Elsevier; 2008:570-604.French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet. 2000;355:2106-2111.Matanock A, Lee G, Gierke R, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Week Repo. 2019;68(46):1069-1075.

   

Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.

   

PP-PRV-IND-0268 July 2022

Prevenar 13® Clinical Experience

Dosing

Help protect your adult patients against pneumococcal pneumonia with single-dose administration

Learn more

   

Recommendations for Use

The ACIP recommends routine use of PCV13 among adults

Learn more

   

FAQs

FAQs related to different fields

Learn more

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-PRV-IND-0268

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 14 July 2022
Yes No
You are now leaving PfizerPro website

​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
​PP-UNP-IND-0012 14 July 2022